Thus, it is plausible that novel pharmacological intervention into the type I IFN/IFNAR axis function, in both adipocytes and immune cells, would provide alternative approaches to dampen type I IFN-driven diseases, including obesity-associated metabolic harm. This evidence concerns the gene IFNAR1 and Obesity.